EA201790922A1 - Ингибиторы бромодомена - Google Patents
Ингибиторы бромодоменаInfo
- Publication number
- EA201790922A1 EA201790922A1 EA201790922A EA201790922A EA201790922A1 EA 201790922 A1 EA201790922 A1 EA 201790922A1 EA 201790922 A EA201790922 A EA 201790922A EA 201790922 A EA201790922 A EA 201790922A EA 201790922 A1 EA201790922 A1 EA 201790922A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bromodomain inhibitors
- compounds
- pharmaceutical compositions
- bromodomain
- inhibit bromodomain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
Abstract
Настоящее изобретение относится к соединениям, ингибирующим бромодомен, фармацевтическим композициям, содержащим соединения, ингибирующие бромодомен, и способам лечения расстройства, отвечающего на модуляцию полипептида из семейства БЭК, с применением описанных соединений и фармацевтических композиций.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068983P | 2014-10-27 | 2014-10-27 | |
PCT/US2015/057538 WO2016069578A1 (en) | 2014-10-27 | 2015-10-27 | Bromodomain inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201790922A1 true EA201790922A1 (ru) | 2017-08-31 |
EA033325B1 EA033325B1 (ru) | 2019-09-30 |
Family
ID=54478264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790922A EA033325B1 (ru) | 2014-10-27 | 2015-10-27 | Ингибиторы бромодомена |
Country Status (20)
Country | Link |
---|---|
US (1) | US10124009B2 (ru) |
EP (1) | EP3212654B1 (ru) |
JP (1) | JP6715243B2 (ru) |
KR (1) | KR20170068597A (ru) |
CN (1) | CN107635979A (ru) |
AU (1) | AU2015339511B2 (ru) |
BR (1) | BR112017008714A2 (ru) |
CA (1) | CA2965330A1 (ru) |
CL (1) | CL2017001046A1 (ru) |
CO (1) | CO2017004898A2 (ru) |
CR (1) | CR20170219A (ru) |
EA (1) | EA033325B1 (ru) |
HK (1) | HK1243415A1 (ru) |
IL (1) | IL251784A0 (ru) |
MX (1) | MX2017005555A (ru) |
PE (1) | PE20171042A1 (ru) |
PH (1) | PH12017500745A1 (ru) |
SG (1) | SG11201703414VA (ru) |
UA (1) | UA122130C2 (ru) |
WO (1) | WO2016069578A1 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
AU2011252808B2 (en) | 2010-05-14 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
SI3640241T1 (sl) | 2013-10-18 | 2023-01-31 | Celgene Quanticel Research, Inc. | Inhibitorji bromodomene |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
US20190247302A1 (en) * | 2016-10-21 | 2019-08-15 | University Of Miami | Materials and methods for treating ophthalmic inflammation |
CN109503618A (zh) * | 2017-09-14 | 2019-03-22 | 成都海创药业有限公司 | 一种brd4抑制剂 |
US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
CN112312916A (zh) | 2018-06-13 | 2021-02-02 | 戴布里股份公司 | 缩合三氮杂卓衍生物的制备及其作为bet抑制剂的用途 |
BR112022012110A2 (pt) | 2019-12-19 | 2022-12-13 | Arvinas Operations Inc | Compostos e métodos para a degradação direcionada de receptor androgênico |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2951540A (en) | 1956-11-05 | 1960-09-06 | Gen Motors Corp | Propeller brake |
US3709898A (en) | 1971-02-09 | 1973-01-09 | Upjohn Co | Process for the production of triazolobenzodiazepines and intermediates |
US3681343A (en) | 1971-05-11 | 1972-08-01 | Upjohn Co | 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines |
US3812259A (en) | 1971-08-09 | 1974-05-21 | Upjohn Co | Animal feed and process |
CH622019A5 (en) | 1975-10-23 | 1981-03-13 | Upjohn Co | Process for the preparation of aminotriazolobenzodiazepines |
FR2329668A1 (fr) | 1975-10-27 | 1977-05-27 | Upjohn Co | Procede de preparation d'aminotriazolobenzodiazepines |
EP0087850A1 (en) | 1982-01-04 | 1983-09-07 | The Upjohn Company | Benzodiazepines for anti-hypertensive use |
DE3435973A1 (de) | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung |
DE3724164A1 (de) | 1986-07-25 | 1988-01-28 | Boehringer Ingelheim Kg | Neue 1,4-benzodiazepine, ihre herstellung und verwendung |
DE3878833T2 (de) | 1987-05-28 | 1993-06-09 | Yoshitomi Pharmaceutical | Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben. |
JPH0676326B2 (ja) | 1988-05-24 | 1994-09-28 | 吉富製薬株式会社 | 循環器系疾患治療薬 |
EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
EP0387613A1 (de) | 1989-03-03 | 1990-09-19 | Boehringer Ingelheim Kg | Neue Thienodiazepine |
YU133090A (sh) | 1989-07-12 | 1993-10-20 | Boehringer Ingelheim Kg. | Novi heteroazepini s paf-antaganostičnim učinkom in postopek za njihovo pripravo |
DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
CA2120939A1 (en) | 1991-10-11 | 1993-04-15 | Tetsuya Tahara | Therapeutic agent for osteoporosis and diazepine compound |
EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
CA2159344A1 (en) | 1993-03-30 | 1994-10-13 | Minoru Moriwaki | Cell adhesion inhibitor and thienotriazolodiazepine compound |
PL316633A1 (en) | 1994-04-01 | 1997-02-03 | Microcide Pharmaceuticals | Cephalosporin antibiotics |
WO1995032963A1 (fr) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienylazole et compose de thienotriazolodiazepine |
ATE203026T1 (de) | 1995-01-06 | 2001-07-15 | Hoffmann La Roche | Hydroxymethyl-imidazodiazepine und deren ester |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
WO1997009048A1 (en) | 1995-09-09 | 1997-03-13 | F. Hoffmann-La Roche Ag | Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
IL127516A0 (en) | 1996-06-12 | 1999-10-28 | Japan Tobacco Inc | A cytokine production inhibitor |
US5693641A (en) | 1996-08-16 | 1997-12-02 | Berlex Laboratories Inc. | Bicyclic pyrimidine derivatives and their use as anti-coagulants |
WO1998011111A1 (fr) | 1996-09-13 | 1998-03-19 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de thienotriazolodiazepine et leurs utilisations a des fins medicinales |
US6444664B1 (en) | 1997-04-18 | 2002-09-03 | Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) | Method for controlling the plasma level of lipoproteins to treat alzheimeris disease |
JPH11228576A (ja) | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
KR20000016732A (en) | 1998-12-12 | 2000-03-25 | Japan Tobacco Inc | Cytokine production inhibitors, triazepine compounds, and intermediates thereof |
US6312215B1 (en) | 2000-02-15 | 2001-11-06 | United Technologies Corporation | Turbine engine windmilling brake |
US7589167B2 (en) | 2000-02-22 | 2009-09-15 | J. David Gladstone Institutes | ZA loops of bromodomains |
KR100838686B1 (ko) | 2000-06-16 | 2008-06-16 | 미쯔비시 웰 파마 가부시키가이샤 | 방출 pH 범위 및/또는 속도 제어 조성물 |
US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
US20060142257A1 (en) | 2001-01-19 | 2006-06-29 | Eberhard Nieschlag | Male contraceptive formulation comprising norethisterone |
US6979682B2 (en) | 2001-02-23 | 2005-12-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Platelet-activating factor antagonist inhibition of angiogenesis and tumor growth induced by basic fibroblast |
US20030216758A1 (en) | 2001-12-28 | 2003-11-20 | Angiotech Pharmaceuticals, Inc. | Coated surgical patches |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
MXPA05009151A (es) | 2003-02-27 | 2005-10-20 | Abbott Lab | Inhibidores de cinasa heterociclica. |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
WO2005002526A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Method and compositions for treatment of viral infections |
CA2538413A1 (en) | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
EP1528056A1 (en) | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
WO2006129623A1 (ja) * | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
PE20071042A1 (es) | 2005-11-04 | 2007-10-12 | Wyeth Corp | Producto farmaceutico que comprende temsirolimus y malato de sunitinib |
SI1962830T1 (sl) | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
CN101370807B (zh) | 2006-01-17 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 可用于经由gaba受体治疗阿尔茨海默病的芳基-异唑-4-基-咪唑并[1,2-a]吡啶 |
WO2007095188A2 (en) | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
US20070218135A1 (en) | 2006-03-14 | 2007-09-20 | Glenmark Pharmaceuticals Limited | Sustained release matrix pharmaceutical composition |
CA2649701A1 (en) | 2006-05-03 | 2007-11-15 | Novartis Ag | Use of organic compounds |
US7621117B2 (en) | 2006-06-19 | 2009-11-24 | Pratt & Whitney Canada Corp. | Apparatus and method for controlling engine windmilling |
ES2631003T3 (es) | 2006-10-19 | 2017-08-25 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos |
US7624617B2 (en) | 2006-11-21 | 2009-12-01 | Asml Netherlands B.V. | Gas analyzing system, lithographic apparatus and method of improving a sensitivity of a gas analyzing system |
WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Brd2ブロモドメイン結合剤 |
WO2008137081A1 (en) | 2007-05-02 | 2008-11-13 | The Trustees Of Columbia University In The City Of New York | Substituted ( 5, 6 ) -dihydronaphraalenyl compounds as reversible male contraceptives |
KR20080107050A (ko) | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
US20110028405A1 (en) | 2007-12-20 | 2011-02-03 | Richard John Harrison | Sulfamides as zap-70 inhibitors |
CN101910182B (zh) | 2007-12-28 | 2013-07-17 | 田边三菱制药株式会社 | 抗癌剂 |
US20110098288A1 (en) | 2008-03-11 | 2011-04-28 | Jeremy Major | Sulfonamides as zap-70 inhibitors |
USPP20436P2 (en) | 2008-04-10 | 2009-10-20 | Driscoll Strawberry Associates, Inc. | Blueberry plant named ‘DrisBlueThree’ |
WO2010015340A1 (en) | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
ES2448567T3 (es) | 2008-10-30 | 2014-03-14 | Circomed Llc | Derivados de la tienotriazoldiazepina activos en apo A |
US9266890B2 (en) | 2009-01-06 | 2016-02-23 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
MY152386A (en) | 2009-01-23 | 2014-09-15 | Takeda Pharmaceutical | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones |
WO2011054644A1 (en) | 2009-10-14 | 2011-05-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | A low density lipoprotein-related protein 1 splice variant as cancer marker |
DK2496580T3 (da) | 2009-11-05 | 2014-02-24 | Glaxosmithkline Llc | Benzodiazepinbromdomænehæmmer |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
CN102781943B (zh) | 2009-11-05 | 2016-10-05 | 葛兰素史密丝克莱恩有限责任公司 | 苯并二氮杂*溴结构域抑制剂 |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
DE102009046518A1 (de) | 2009-11-09 | 2011-05-12 | Robert Bosch Gmbh | Speicheranordnung |
US20120329803A1 (en) | 2010-02-17 | 2012-12-27 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
US9624870B2 (en) | 2010-03-26 | 2017-04-18 | Rolls-Royce North American Technologies, Inc. | Adaptive fan system for a variable cycle turbofan engine |
AU2011252808B2 (en) | 2010-05-14 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
JP6022442B2 (ja) * | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 男性用避妊組成物および使用方法 |
EP2569429A4 (en) | 2010-05-14 | 2013-09-25 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND METHOD OF METABOLIC MODULATION |
US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランn−スルファターゼのcns送達のための方法および組成物 |
US20120014979A1 (en) | 2010-07-16 | 2012-01-19 | Alexander Dent | Use of bcl6 inhibitors for treating autoimmune diseases |
TWI583689B (zh) | 2010-08-04 | 2017-05-21 | 達納 法柏癌症學院有限公司 | 治療腫瘤形成、發炎疾病及其他病症之組成物及方法 |
WO2012050907A2 (en) | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
AU2012220620A1 (en) | 2011-02-23 | 2013-10-03 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
ES2951688T3 (es) | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
JP2014524409A (ja) | 2011-07-29 | 2014-09-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | Hivの治療のための組成物および方法 |
FI20110279A0 (fi) | 2011-08-29 | 2011-08-29 | Outotec Oyj | Menetelmä metallien talteenottamiseksi niitä sisältävästä materiaalista |
WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
US10071129B2 (en) | 2011-08-30 | 2018-09-11 | Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. | Method for identifying bromodomain inhibitors |
DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
AU2013221230A1 (en) | 2012-02-17 | 2014-10-02 | Ansun Biopharma, Inc. | Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients |
US20150133434A1 (en) | 2012-03-28 | 2015-05-14 | The J. David Gladstone Institutes | Compositions and Methods for Reactivating Latent Immunodeficiency Virus |
WO2013192274A2 (en) | 2012-06-19 | 2013-12-27 | The Broad Institute, Inc. | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy |
CA2885944A1 (en) | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
WO2014071247A1 (en) | 2012-11-02 | 2014-05-08 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors |
EP2958922A1 (de) | 2013-02-22 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen |
CA2901805A1 (en) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
JP2016510039A (ja) * | 2013-02-28 | 2016-04-04 | ワシントン・ユニバーシティWashington University | ブロモドメイン阻害剤によるヒトサイトメガロウイルス感染および疾患の治療方法 |
US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
JP2016519672A (ja) | 2013-03-15 | 2016-07-07 | ジェネンテック, インコーポレイテッド | ブロモドメイン含有タンパク質brd7およびbrd9の阻害によるth2媒介性疾患の治療 |
CN105358150A (zh) | 2013-05-28 | 2016-02-24 | 达纳-法伯癌症研究所有限公司 | 用于心脏病的bet抑制疗法 |
BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
KR20160037201A (ko) | 2013-08-06 | 2016-04-05 | 온코에틱스 게엠베하 | Bet-브로모도메인 억제제를 사용한 미만성 거대 b-세포 림프종 (dlbcl)의 치료 방법 |
WO2015023938A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
EP3047276B1 (en) | 2013-09-19 | 2023-06-14 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
JP2016534044A (ja) | 2013-10-11 | 2016-11-04 | ジェネンテック, インコーポレイテッド | 癌の免疫療法のためのcbp/ep300ブロモドメインインヒビターの使用 |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
WO2015081284A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
CN105940005A (zh) | 2014-01-31 | 2016-09-14 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
US10813939B2 (en) | 2014-12-05 | 2020-10-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bromodomain inhibitor as adjuvant in cancer immunotherapy |
JP2018520124A (ja) | 2015-06-26 | 2018-07-26 | テンシャ セラピューティクス,インコーポレイテッド | Nut正中線癌の治療 |
CN108289957A (zh) | 2015-10-02 | 2018-07-17 | 达纳-法伯癌症研究所股份有限公司 | 溴区结构域抑制剂和检查点阻断的组合疗法 |
-
2015
- 2015-10-27 EP EP15791448.2A patent/EP3212654B1/en active Active
- 2015-10-27 UA UAA201704436A patent/UA122130C2/uk unknown
- 2015-10-27 EA EA201790922A patent/EA033325B1/ru not_active IP Right Cessation
- 2015-10-27 CA CA2965330A patent/CA2965330A1/en not_active Abandoned
- 2015-10-27 JP JP2017522518A patent/JP6715243B2/ja not_active Expired - Fee Related
- 2015-10-27 CN CN201580070259.6A patent/CN107635979A/zh active Pending
- 2015-10-27 KR KR1020177013650A patent/KR20170068597A/ko not_active Application Discontinuation
- 2015-10-27 MX MX2017005555A patent/MX2017005555A/es active IP Right Grant
- 2015-10-27 CR CR20170219A patent/CR20170219A/es unknown
- 2015-10-27 US US15/522,222 patent/US10124009B2/en not_active Expired - Fee Related
- 2015-10-27 AU AU2015339511A patent/AU2015339511B2/en not_active Ceased
- 2015-10-27 PE PE2017000761A patent/PE20171042A1/es unknown
- 2015-10-27 SG SG11201703414VA patent/SG11201703414VA/en unknown
- 2015-10-27 WO PCT/US2015/057538 patent/WO2016069578A1/en active Application Filing
- 2015-10-27 BR BR112017008714A patent/BR112017008714A2/pt not_active IP Right Cessation
-
2017
- 2017-04-19 IL IL251784A patent/IL251784A0/en active IP Right Grant
- 2017-04-21 PH PH12017500745A patent/PH12017500745A1/en unknown
- 2017-04-27 CL CL2017001046A patent/CL2017001046A1/es unknown
- 2017-05-16 CO CONC2017/0004898A patent/CO2017004898A2/es unknown
-
2018
- 2018-03-02 HK HK18103024.4A patent/HK1243415A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PH12017500745A1 (en) | 2017-10-30 |
US10124009B2 (en) | 2018-11-13 |
HK1243415A1 (zh) | 2018-07-13 |
CR20170219A (es) | 2017-08-14 |
CA2965330A1 (en) | 2016-05-06 |
SG11201703414VA (en) | 2017-05-30 |
UA122130C2 (uk) | 2020-09-25 |
EA033325B1 (ru) | 2019-09-30 |
IL251784A0 (en) | 2017-06-29 |
AU2015339511A1 (en) | 2017-05-18 |
JP2017531688A (ja) | 2017-10-26 |
PE20171042A1 (es) | 2017-07-19 |
EP3212654B1 (en) | 2020-04-08 |
CN107635979A (zh) | 2018-01-26 |
US20170333444A1 (en) | 2017-11-23 |
CL2017001046A1 (es) | 2018-01-26 |
BR112017008714A2 (pt) | 2017-12-19 |
CO2017004898A2 (es) | 2017-10-31 |
AU2015339511B2 (en) | 2020-05-14 |
KR20170068597A (ko) | 2017-06-19 |
MX2017005555A (es) | 2018-02-09 |
JP6715243B2 (ja) | 2020-07-01 |
EP3212654A1 (en) | 2017-09-06 |
WO2016069578A1 (en) | 2016-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790922A1 (ru) | Ингибиторы бромодомена | |
EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
EA201891087A1 (ru) | Ингибиторы ret | |
CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
EA201592143A1 (ru) | Новые бициклические ингибиторы бромодомена | |
EA201890712A1 (ru) | Антитела к про-/латентному миостатину и их применения | |
EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
EA201691974A1 (ru) | Антитела против ox40 и способы их применения | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
EA201890052A1 (ru) | Регуляторы nrf2 | |
EA201891251A1 (ru) | Бициклические ингибиторы pad4 | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
EA201692204A1 (ru) | Композиции и способы модулирования экспрессии фактора комплемента b | |
EA201691397A1 (ru) | Хинолиновые ингибиторы киназы | |
EA201891347A1 (ru) | Аза-бензимидазольные ингибиторы pad4 | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
EA201791174A1 (ru) | Антимикотическое соединение | |
EA201792262A1 (ru) | Пироглутамат вортиоксетина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |